No Data
ReproCELL: Half-Year Report - Term 23 (2024/04/01－2025/03/31)
ReproCELL: Confirmation letter
ReproCELL: 2nd Half (Mid-Term) Decision SMS for March 2025 [Japan Basis] (link)
Medrek, Replcell, and others
<3185> Dream Vision 11th subscription rights (with exercise price adjustment clause) The large number of shares to be issued from the 28th, 0.5 million shares <4586> Medorek MRX-7MLL to start clinical trials <4588> Oncolis Bio 20th subscription rights (with exercise price adjustment clause) The large number of shares to be issued from the 18th, 0.51 million and 2000 shares <4598> DELTA-PDFP-10917 and VEN's progress in Phase 1/2 clinical trials <4883> Modalis 14th subscription rights
Supported by a firm US stock market, but there may be a heavy resistance to price increases.
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a strong performance. In the U.S. stock market on the 16th, the Dow Jones Industrial Average rebounded by 337.28 points (+0.79%) to 43,077.70 points. The positive earnings reports from airlines and financial companies, as well as the rise in stock prices of semiconductor Nvidia (NVDA), have improved investor sentiment. Expectations for a soft landing and the decrease in long-term interest rates have also become supporting factors for stock prices. It seems that buying will dominate the development in today's emerging markets, as the major indices rose in the U.S. stock market yesterday.
Deere & Co, RepliCel, and others [Emerging Markets Press Release]
Following the company split (simplified establishment split) at <155A>, a subsidiary was established. At <3935>, deere & co requested a market change to the Tokyo Stock Exchange's standard market. At <4978>, Cell AMED received approval for the market change. The grant amount for the 2023 fiscal year for the Public Offering Business 'Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy' has been determined.
No Data
No Data